A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CEFTAZIDIME AND AVIBACTAM IN NEONATES AND INFANTS FROM BIRTH TO LESS THAN 3 MONTHS OF AGE WITH SUSPECTED OR CONFIRMED INFECTIONS DUE TO GRAM-NEGATIVE PATHOGENS REQUIRING INTRAVENOUS ANTIBIOTIC TREATMENT

Pfizer Inc. 235 East 42nd Street, New York, New York 100170 个研究点目标入组 48 人开始时间: 2019年11月5日最近更新: 2020年2月1日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 48

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

入选标准

•Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:
•Inclusion Criteria for All Subjects:
•1.Evidence of a personally signed and dated informed consent document indicating that the subject’s parent(s), legal guardian, or legally acceptable representative has been informed of all pertinent aspects of the study.
•2.Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
•3.Male or female neonates and infants with age at Screening:
•a.Cohort 1: Full term infants (gestational age =37 weeks) with chronological age >28 days to <3 months (89 days) or pre-term infants with corrected age* >28 days to <3 months (89 days). A maximum of 3 pre-term corrected age infants may be enrolled in each part (A and B) of Cohort 1. Sites will be notified in writing if this limit is reached.
•b.Cohort 2: Full term neonates (gestational age =37 weeks) from birth to =28 days.
•c.Cohort 3: Pre-term neonates (gestational age =26 to <37 weeks) from birth to =28 days.
•Gestational age is the time elapsed between the first day of the last menstrual period and birth.
•*Corrected age is the age of the infant from the expected date of delivery, calculated by subtracting the number of weeks born before 40 weeks of gestation from the chronological age (Engle, 2004). Corrected age (in weeks) = chronological age in weeks – (40 – gestational age in weeks). See Protocol (Appendix 2) for calculation of corrected age in days and alternative perinatal age terminologies.
•Inclusion Criteria for Part A Subjects Only:
•1.Hospitalized and receiving intravenous antibacterial therapy for the treatment of a suspected or confirmed bacterial infection.
•Inclusion Criteria for Part B Subjects Only:
•1.Hospitalized with suspected or confirmed aerobic Gram-negative bacterial infection requiring intravenous antibacterial therapy.
•2.Subjects must meet at least 1 clinical and 1 laboratory criterion or meet at least 2 of the clinical criteria:
•Clinical Criteria:
•a.Hypothermia (<36°C) OR fever (>38.5°C);
•b.Bradycardia OR tachycardia OR rhythm instability;
•c.Urine output 0.5 to 1 mL/kg/h OR hypotension OR mottled skin OR impaired peripheral perfusion;
•d.Petechial rash OR sclerema neonatorum;
•e.New onset or worsening of apnea episodes OR tachypnea episodes OR increased oxygen requirements OR requirement for ventilation support;
•f.Feeding intolerance OR poor suckling OR abdominal distension;
•g.Irritability;
•h.Lethargy;
•i.Hypotonia.
•Laboratory Criteria:
•a.White blood cell count =4.0 × 109/L OR =20.0 × 109/L;
•b.Immature to total neutrophil ratio >0.2;
•c.Platelet count =100 × 109/L;
•d.C-reactive protein (CRP) >15 mg/L OR procalcitonin =2 ng/mL;
•e.Hyperglycemia OR Hypoglycemia;
•f.Metabolic acidosis.
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 48
•F.1.2 Adults (18-64 years) no

排除标准

•Subjects with any of the following characteristics/conditions will not be included in the study:
•Exclusion Criteria for All Subjects:
•1.Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
•2.Participation in another clinical study involving investigational drug(s) within 30 days prior to study entry and/or during this study participation or have previously participated in the current study or in another study of CAZ AVI (in which an active agent was received).
•3.Use of potent inhibitors of organic anion transporters OAT1 and/or OAT3 (eg, probenecid, p-aminohippuric acid (PAH), or teriflunomide) are prohibited. This prohibition of OAT1 and/or OAT3 inhibitors also applies to the mothers of any neonates or infants who are breast feeding during the trial.
•4.Other acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.
•5.Documented history of any hypersensitivity or allergic reaction to any ß-lactam antibiotic.
•6.Refractory septic shock within 24 hours before screening that does not resolve after 60 minutes of vasopressor therapy.
•7.Moderate or severe renal impairment defined as serum creatinine =2 times the upper limit of normal (ULN) for age OR urine output <0.5 mL/kg/h (measured over at least 8 hours) OR requirement for dialysis. Deterioration of renal function after enrollment during Part B of the study will be handled on a case-by-case basis in discussion with the Medical Monitor (see Section 5.5.2 of the protocol).
•8.Evidence of progressively fatal underlying disease, or life expectancy of =60 days.
•9.Documented history of seizure.
•10.Active acute viral hepatitis or acute hepatic failure.
•11.Known Clostridium difficile associated diarrhea.
•12.Requiring or currently taking antiretroviral therapy for human immunodeficiency virus (HIV) or known HIV positive mother.
•13.Any condition (eg, cystic fibrosis, urea cycle disorders), antepartum/peripartum factors, or procedures that would, in the opinion of the Investigator, make the subject unsuitable for the study, place a subject at risk, or compromise the quality of data.
•14.Treatment with ceftazidime within 12 hours of CAZ-AVI administration.
•Exclusion Criteria for Part A Subjects Only:
•1.Subject received a blood or a blood component transfusion within 24 hours of the start of CAZ-AVI infusion.
•2.Subject is expected to be discharged less than 24 hours after the start of CAZ-AVI infusion.
•Exclusion Criteria for Part B Subjects Only:
•1.At study entry, subject has confirmed or strongly suspected infection with a pathogen known to be resistant to CAZ-AVI or only a Gram-positive pathogen or viral, fungal, or parasitic pathogens as the sole cause of infection.

研究者

发起方

Pfizer Inc. 235 East 42nd Street, New York, New York 10017

相似试验

进行中（未招募）

1 期

Treatment for infections due to Gram-Negative Pathogens Infection in infants from birth to 3 months old.Infections with suspected or confirmed Gram-negative pathogensMedDRA version: 20.0Level: LLTClassification code 10032531Term: Other specified bacterial infections in conditions classified elsewhere and of unspecified siteSystem Organ Class: 100000004862

EUCTR2018-002800-16-GRPfizer Inc. 235 East 42nd Street, New York, New York 1001746

进行中（未招募）

1 期

EUCTR2018-002800-16-SKPfizer Inc.48

进行中（未招募）

1 期

EUCTR2018-002800-16-ITPFIZER INC44

进行中（未招募）

1 期

Treatment for infections due to Gram-Negative Pathogens Infection in infants from birth to 3 months old.Infections with suspected or confirmed Gram-negative pathogensMedDRA version: 20.0 Level: LLT Classification code 10032531 Term: Other specified bacterial infections in conditions classified elsewhere and of unspecified site System Organ Class: 100000004862

EUCTR2018-002800-16-HUPfizer Inc. 235 East 42nd Street, New York, New York 1001748

尚未招募

2 期

Study of ceftazidime and avibactam in neonates and infants from birth to less than 3 months of age who is having infection or can have infaction and require antibiotic treatment.

CTRI/2020/02/023439Pfizer Inc